Selected Publications
Publications
2019
Journal Articles- Refereed
Degeling K, Koffijberg H, Franken MD, Koopman M, IJzerman MJ. Comparing Strategies for Modeling Competing Risks in Discrete-Event Simulations: A Simulation Study and Illustration in Colorectal Cancer. Med Decis Making. 4 ed. 2018 Dec 27;39(1):57–73.
2018
Journal Articles- Refereed
Broekhuizen H, Groothuis-Oudshoorn CGM, Vliegenthart R, Groen HJM, IJzerman MJ. Assessing Lung Cancer Screening Programs under Uncertainty in a Heterogeneous Population. Value Health. 2018 Nov;21(11):1269–77.
Degeling K, Franken MD, May AM, van Oijen MGH, Koopman M, Punt CJA, IJzerman MJ et al. Matching the model with the evidence_ comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients. Cancer Epidemiol. Elsevier; 2018 Oct 12;57:60–7.
Heuvelmans MA, Vonder M, Rook M, Groen HJM, de Bock GH, Xie X, et al. Screening for Early Lung Cancer, Chronic Obstructive Pulmonary Disease, and Cardiovascular Disease (the Big-3) Using Low-dose Chest Computed Tomography: Current Evidence and Technical Considerations. J Thorac Imaging. 2018 Dec 13;:1.
de Wit S, Manicone M, Rossi E, Lampignano R, Yang L, Zill B, et al. EpCAMhigh and EpCAMlow circulating tumor cells in metastatic prostate and breast cancer patients. Oncotarget. 2018 Nov 2;9(86):35705–16.
Berghuis AMS, Koffijberg H, Terstappen LWMM, Sleijfer S, IJzerman MJ. Evidence on the cost of breast cancer drugs is required for rational decision making. Ecancermedicalscience. 2018;12:825.
IJzerman MJ, Berghuis AMS, de Bono JS, Terstappen LWMM. Health economic impact of liquid biopsies in cancer management. Expert Rev Pharmacoecon Outcomes Res. 2018 Aug 7;28(1):1–7.
Witteveen A, Nane GF, Vliegen IMH, Siesling S, IJzerman MJ. Comparison of Logistic Regression and Bayesian Networks for Risk Prediction of Breast Cancer Recurrence. Medical Decision Making. 2018 Oct; 38(7):822-833
Witteveen A, Siesling S, Otten JWM, Vliegen IMH, Timmer JB, IJzerman MJ. Risk-based breast cancer follow-up stratified by age. Cancer Med. 2018 Oct; 7(10):5291-5298
2017
Journal Articles- Refereed
Berghuis AMS, Koffijberg H, Prakash J, Terstappen LWMM, IJzerman MJ. Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility. Int J Mol Sci. Multidisciplinary Digital Publishing Institute; 2017 Feb 9;18(2):363.
Brinkhof S, Groen HJM, Siesling SS, IJzerman MJ. Resource utilization in lung cancer diagnostic procedures: Current use and budget consequences. PLoS ONE. 2017 Dec 7;12(12):e0189251–7.
Broekhuizen H, Groothuis-Oudshoorn CGM, Vliegenthart R, Groen H, IJzerman MJ. Public Preferences for Lung Cancer Screening Policies. Value Health. 2017 Aug;20(7):961–8.
Crown W, Buyukkaramikli N, Thokala P, Morton A, Sir MY, Marshall DA, IJzerman MJ et al. Constrained Optimization Methods in Health Services Research-An Introduction: Report 1 of the ISPOR Optimization Methods Emerging Good Practices Task Force. Value Health. 2017 Mar;20(3):310–9.
Degeling K, IJzerman MJ, Koopman M, Koffijberg H. Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models. BMC Med Res Methodol; 2017 Dec 15;17(1):170–12.
Degeling K, Koffijberg H, IJzerman MJ. A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level models. Expert Rev Pharmacoecon Outcomes Res. Taylor & Francis; 2017 Feb;17(1):17–25.
Degeling K, Schivo S, Mehra N, Koffijberg H, Langerak R, de Bono JS, IJzerman MJ. Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-Resistant Prostate Cancer. Value in Health. 2017 Jul;in press(10):1411–9.
Mewes JC, Steuten LMG, IJzerman MJ, van Harten WH. A systematic approach for assessing, in the absence of full evidence, whether multicomponent interventions can be more cost-effective than single component interventions. Int J Technol Assess Health Care. 2017 Sep 11;:1–10.
Mewes JC, Steuten LMG, IJsbrandy C, IJzerman MJ, van Harten WH. Value of Implementation of Strategies to Increase the Adherence of Health Professionals and Cancer Survivors to Guideline-Based Physical Exercise. Value in Health. 2017 Jun.
Otten JWM, Witteveen A, Vliegen IMH, Siesling S, Timmer JB, IJzerman MJ. Stratified Breast Cancer Follow-Up Using a Partially Observable MDP. In: Markov Decision Processes in Practice. Cham: Springer, Cham; 2017. pp. 223–44. (International Series in Operations Research & Management Science; vol. 248).
van Harten W, IJzerman MJ. Responsible pricing in value-based assessment of cancer drugs: real-world data are an inevitable addition to select meaningful new cancer treatments. Ecancermedicalscience. 2017;11:ed71.
2016
Journal Articles- Refereed
Malone DC, Berg NS, Claxton K, Garrison LP, IJZERMAN M, Marsh K, et al. International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework. J Clin Oncol. American Society of Clinical Oncology; 2016 Aug 20;34(24):2936–7.
2015
Journal Articles- Refereed
Mewes JC, Steuten LMG, Groeneveld IF, de Boer AGEM, Frings-Dresen MHW, IJZERMAN MJ, et al. Return-to-work intervention for cancer survivors: budget impact and allocation of costs and returns in the Netherlands and six major EU-countries. BMC Cancer. 2015 Nov 12;15(1):899.